Technology/ Title

Development of CSF-1R antibody drug to target tumor associated macrophage for cancer immunotherapy

Technology Type

□Biotechnology

□Device/Diagnostics

■Pharmaceutical

□Others:_____________-

Contact Person

Name: Kuan-Tsung Lin

Title: Project Manager

Telephone(work): +886-02-7700-3800  ext. 5239

Email:

ktlin2@dcb.org.tw

2019 BioAsia

Information

Download

https://www.dcb.org.tw/posts/729

 

 

Technology Description

 
  • Summary of Invention:
  1. CSF-1R (colony-stimulating factor-1 receptor) is a cell surface receptor for the macrophage colony stimulating factor (M-CSF or CSF-1) and IL-34. It is required for the proliferation and survival and differentiation of cells of monocyte/macrophage lineage. Elevated expression or activation of CSF-1R and/or its ligand has been found in a variety of cancers, and elevated levels of M-CSF are associated with poor prognosis in certain cancers. M-CSF is one of several cytokines implicated in the recruitment of tumor-associated macrophages (TAMs), which exhibit similar characteristics to M2 macrophages and contribute to tumor angiogenesis and tumor progression to metastasis. Targeting TAM through CSF-1R signaling by neutralizing antibody is therefore an attractive strategy to treat oncological and inflammatory/immunological diseases.
  2. This CSF-1R lead antibody shows high affinity, neutralizing ability, novel CDRs sequence and non-overlapping epitopes with other CSF-1R antibodies. US provisional patent was filed.
  • Advantages when compared to the existing technologies:
  1. In vitro & in vivo platforms for CSF-1R antibody screening.
  2. Characterization and analytical platforms for CSF-1R antibody.
  3. Novel CDRs and novel epitopes for DCB’s CSF-1R antibody.
  4. Potential to combine with PD-1/PD-L1 antibody.

 

Intellectual Property

US provisional patent applied

Business Opportunity

Immune-oncology cancer therapy